SIGNAL // LOADING
Loading page
Glossary term
Mounjaro
Also known as Tirzepatide (T2D indication)
Brand-name tirzepatide FDA-approved for type 2 diabetes - and prescribed off-label for weight loss when coverage permits.
Mounjaro is Eli Lilly's once-weekly tirzepatide formulation for type 2 diabetes. SURPASS trials showed 2.0-2.4% HbA1c reduction at max dose plus substantial secondary weight loss. It is not FDA-approved for weight loss - Zepbound carries that indication. Dosing starts at 2.5 mg weekly and titrates through five steps. Shares the same contraindications as tirzepatide generally.
Medically reviewed byDr. Lena Okafor, MD
Medical Director - updated April 2026How we review
External references
Related
Connected context
Related terms
Related guides
GLP-1 eligibility explained: who qualifies, who doesn't, and whyTirzepatide vs semaglutide: how to think about the choiceWhat a comprehensive metabolic panel actually tells youProvider-reviewed care vs DIY supplementation: when each makes sensePCOS labs: the markers that actually drive the planGLP-1 side effects: what's normal, what needs review, what stops the protocolHolding the loss after GLP-1: protein, training, and the maintenance planFasting insulin and HOMA-IR: the metabolic signal that precedes A1c by yearsCreatine, protein, and the two supplements that actually moved your labsWeight-loss plateaus on GLP-1: what to change first